2016 American Transplant Congress
Recall Alloantibody Production Is Driven by CD138+ Cells Proliferating in the Spleens: An Indication for Long-Lived Plasma Cell Activities and Potential Therapeutic Target.
Comprehensive Transplantation Center/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Background Donor-specific antibodies (DSA) generated in recall responses are produced by long-lived plasma cells (L-PC) residing in the bone marrows (BM). Mechanisms of L-PC activation,…2016 American Transplant Congress
IL-10 Expression of In Vitro Activated B Cells as A Biomarker for B Cell Tolerance.
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
Background: A significant role for regulatory B cell has been suggested in kidney transplant recipients who achieved operational tolerance while receiving conventional immunosuppression. We studied…2016 American Transplant Congress
Targeting IFN-g-Expressing TIM-4+ B Effector (Beff) Cells as a Novel Strategy to Prevent Allograft Rejection.
1University of Pittsburgh, Pittsburgh; 2Harvard Medical School, Boston.
B cell depletion can augment or inhibit auto- and allo- immune responses in humans and mice without altering Ig levels. This is likely due to…2016 American Transplant Congress
Alloantibody Suppression by Bruton Tyrosine Kinase Antagonist Ibrutinib Is Associated with a Moderate Splenic B-Cell Reduction.
Comprehensive Transplantation Center/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Background Bruton tyrosine kinase (Btk) is specifically required for activation of the B-cell antigen receptor signaling pathway that contributes to the initiation and maintenance of…2016 American Transplant Congress
Acquired Down-Regulation of B Cell Function Induced by Donor Blood Group Antigens After ABO-Incompatible Kidney Transplantation.
Background: The long-term of B cell immunobiology against donor blood group antigen has not been elucidated in ABO incompatible kidney transplantation (ABOi KTx).Methods: The antibody…2016 American Transplant Congress
B Cell Signature Profiling in Kidney Transplant Patients on Thymoglobulin.
Purpose: B cell subsets could be used as biomarkers to modulate therapy regimens in kidney transplant patients. B cell subsets occur with varying proportions within…2016 American Transplant Congress
HLA Antibody Clonality and Epitopes Dictate Complement Activation.
Background: Alloimmunization results in production of polyclonal donor specific antibodies (DSA) against human leukocyte antigens (HLA), which mediate endothelial cell activation, leukocyte recruitment, and complement…2016 American Transplant Congress
First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: There is extensive experience with rituximab (RTX,Type I anti-CD20) for desensitization (DES) and treatment of ABMR. There is also a comparable experience in treatment…2016 American Transplant Congress
Everolimus Decline Anti-ABO Blood Type Antibody Titer in Desensitization for ABO Incompatible Kidney Transplantation.
Kidney Transplantation Surgery, Sapporo City General Hospital, Sapporo, Hokkaido, Japan.
INTRODUCTION: The immoderate donor shortage and sophisticated desensitization protocols resulted in the explosive increase and great success of the ABO blood type incompatible kidney transplantation…2016 American Transplant Congress
Initial Experience with the Bacterial Enzyme IdeS® (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Patients.
Introduction: The IgG degrading enzyme derived from Streptococcus pyogenes (IdeS®) is a 35k-Da cysteine protease that cleaves human IgG molecules at the lower hinge region…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 35
- Next Page »